Thursday, October 1, 2026

Back to today

From X

ZTS · long

Zoetis INC

Zoetis, the animal prescription-medicines company, is presented as a long investment despite concerns around its 2026 and 2027 outlook.

CYD and H22 Results First Take:

CYD’s FY24 earnings miss reflected ¥200m of one-offs; adjusted net income reached roughly ¥430m and operating cash flow rose 40%.

Publications we follow

Every publication on this site, hand-picked.

110 publications

Newsletters 93

X accounts we follow

Every account on this site, hand-picked.

73 accounts

Investor letters we follow

189 firms

Sectors

Ordered by how often our editor reaches for them.